

## FDA Announces Device Trial Participation Snapshots

October 23, 2024

Reading Time: 1 min

By: Nathan A. Brown, Marlee P. Gallant

FDA's Center for Devices and Radiological Health (CDRH) <u>recently announced</u> a pilot program to provide consumers and health care professionals with key information about clinical trials that supported the FDA's approval of new medical devices. This program is modeled after the Center for Drug Evaluation and Research (CDER) <u>drug trials snapshots program</u>. The snapshots address questions about who participated in clinical studies of new medical technology and what clinical trial information is available about how it works in different groups of people. Snapshots are currently available for approvals of higher risk devices approved under original premarket approval (PMA) applications from April to July 2024. The snapshots only provide information that was available at the time of approval, and the FDA does not plan to update them over time, with real-world data, for example.

This pilot program is part of the FDA's ongoing <u>effort</u> to increase transparency around diversity of clinical trial participants in studies of novel medical products.

Comments on the snapshots pilot program may be submitted to <u>www.Regulations.gov</u> under docket number FDA-2024-N-4561 by January 13, 2025.

## **Categories**

Akin

Medical Devices Health Care Regulatory

Food and Drug Administration (FDA)

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.

